Real-World Efficacy and Safety of Tafluprost in Primary Open-Angle Glaucoma Patients with Corneal Disorders: A Taiwan Experience

Table 1

Demographics and baseline characteristics of enrolled patients.

Variable	Results (N = 17)
Sex (n, %)
Male	11 (64.7%)
Female	6 (35.3%)
Age (mean ± SD; years)	62.2 ± 10.6
Diagnosis, right eye (n, %)
POAG	17 (100.0%)
OH	0
Others	0
Duration of diagnosis (mean ± SD; months)	48.8 ± 37.6
Diagnosis, left eye (n, %)
POAG	16 (94.0%)
OH	0
Others	1 (6.0%)
Duration of diagnosis (mean ± SD; months)	45.9 ± 36.9
Study eye (n, %)
Right	9 (53.0%)
Left	8 (47.0%)
Concomitant ocular medications (n, %)
Sulfamethoxazole	10 (58.8%)
Pirenoxine	8 (47%)
Cyanocobalamin	4 (23.5%)
Neostigmine	3 (17.6%)

OH, ocular hypertension; POAG, primary open-angle glaucoma; SD, standard deviation.